The company was renamed "Jiangsu Aidea Pharmaceutical Group Co., Ltd."

The marketing application for Atribond® new drug was approved by the Zambia Food and Drug Administration (ZFDA)

Phase III clinical trial of the novel integrase inhibitor ACC017 was officially launched

ADB116 for injection, an improved new drug in the stroke field, was approved for clinical trials

Dr. Heliang Fu released the Phase II clinical results of Asuptegravir at the 10th Medical Innovation and Investment Conference

ADC118 Tablets, a Class 1 new drug in the anti-HIV field, was approved for clinical trials